SCTX Stock Forecast & Price Target

Scribe Therapeutics is attractive because STX-1150 combines durable PCSK9 silencing with a one-infusion profile that could preserve LDL-C lowering for years, addressing the poor persistence that limits statins, ezetimibe, and even PCSK9 therapies in real-world use. Its preclinical package is compelling, with >5x greater potency in primary human hepatocytes than NHP hepatocytes, saturated PCSK9 repression at ≥0.6 mg/kg in humanized mice, and >50% LDL-C lowering maintained for two years in NHPs, while safety signals have remained manageable with no test-article-related adverse findings and ALT comparable to saline controls at 0.75 mg/kg. Financially, the stock appears undervalued at a ~$540M market value and ~$360M EV versus Verve’s ~$549M net-of-cash acquisition benchmark, and the large addressable population of roughly 7M U.S. adults supports meaningful upside if 1H27 human data confirm safe, durable ≥50% LDL-C reduction.

Scribe Therapeutics is a pre-revenue, clinical-stage biotech with no product sales and persistent losses, so its valuation rests almost entirely on unproven pipeline execution rather than current fundamentals. The company’s first asset, STX-1150, has only just entered the clinic, while first-in-human data are not expected until 1H27 and platform value depends on later XE human dose-response data in likely 2028 or later, leaving long development timelines and substantial execution risk. Even with estimated cash of about $170M and runway into 1H29, management does not expect funding through approval, and dilution, financing, manufacturing, IP, safety, and competitive PCSK9 pressures could materially undermine returns.